|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
To test the role of the FGF19/FGFR4 system in tumor progression, we used recombinant FGF19 protein and small interfering RNA (siRNA) of FGF19 and FGFR4 to regulate their concentrations.
|
22309595 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4.
|
17599042 |
2008 |
|
Constipation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
To identify differences in faecal bile acids, faecal fat and fasting serum C4 (7a-hydroxy-4-cholesten-3-one) and fibroblast growth factor 19 (FGF19) among patients with IBS-D, IBS-C and healthy controls and to determine accurate, cost-effective biomarkers for clinically relevant diarrhoea and constipation.
|
30740753 |
2019 |
|
Bile acid diarrhea
|
0.070 |
Biomarker
|
disease |
BEFREE |
To explore if an impaired FGF19 response identifies primary bile acid diarrhoea.
|
28378364 |
2017 |
|
Functional diarrhea
|
0.010 |
Biomarker
|
disease |
BEFREE |
To analyse prevalence, specificity and reproducibility of fasting C4 and FGF19 in identifying bile acid diarrhoea in patients with irritable bowel syndrome with predominant diarrhoea or functional diarrhoea (summarised as IBS-D).
|
28691284 |
2017 |
|
Diarrhea
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
To analyse prevalence, specificity and reproducibility of fasting C4 and FGF19 in identifying bile acid diarrhoea in patients with irritable bowel syndrome with predominant diarrhoea or functional diarrhoea (summarised as IBS-D).
|
28691284 |
2017 |
|
Irritable Bowel Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
To analyse prevalence, specificity and reproducibility of fasting C4 and FGF19 in identifying bile acid diarrhoea in patients with irritable bowel syndrome with predominant diarrhoea or functional diarrhoea (summarised as IBS-D).
|
28691284 |
2017 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the <i>FGF19-FGFR4</i> signaling pathway is a promising target for the treatment of HCC.
|
31167419 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, it is imperative to understand which cancers are oncogenically addicted to FGF19 amplification as well as the role it serves in these cancer types.
|
30518874 |
2019 |
|
Metabolic Syndrome X
|
0.220 |
Biomarker
|
disease |
BEFREE |
This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-<i>α</i> function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).
|
29765501 |
2018 |
|
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-<i>α</i> function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).
|
29765501 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study explored the potential of FGF19- and FGFR4-related biomarkers in predicting early tumour recurrence (ETR) and survival in patients with resectable hepatocellular carcinoma (HCC).
|
30698907 |
2019 |
|
Hepatoma resectable
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study explored the potential of FGF19- and FGFR4-related biomarkers in predicting early tumour recurrence (ETR) and survival in patients with resectable hepatocellular carcinoma (HCC).
|
30698907 |
2019 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the association of serum FGF19 levels with obesity and visceral fat accumulation in a Chinese population with differing glucose tolerance status.
|
29174027 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review presents a brief overview of the FGF family, describing the mode of action of the different FGFs subgroups, and focuses on FGF1 and FGF15/FGF19, which appear to also represent promising new targets for the treatment of obesity and type 2 diabetes.
|
27412358 |
2017 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review presents a brief overview of the FGF family, describing the mode of action of the different FGFs subgroups, and focuses on FGF1 and FGF15/FGF19, which appear to also represent promising new targets for the treatment of obesity and type 2 diabetes.
|
27412358 |
2017 |
|
Primary cholangitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This gut-liver FXR-FGF19 dual action is the paradigm of physiological BA regulation and it is currently targeted in the clinical practice for liver disease such as primary cholangitis.
|
30223181 |
2018 |
|
Liver diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
This gut-liver FXR-FGF19 dual action is the paradigm of physiological BA regulation and it is currently targeted in the clinical practice for liver disease such as primary cholangitis.
|
30223181 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Colonic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
|
17599042 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection.<i>See related commentary by Subbiah and Pal, p. 1646</i>.<i>This article is highlighted in the In This Issue feature, p. 1631</i>.
|
31575541 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that ASP5878 is a potentially effective therapeutic agent for hepatocellular carcinoma patients with tumors expressing fibroblast growth factor 19.Mol Cancer Ther; 16(1); 68-75.©2016 AACR.
|
27837028 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that ASP5878 is a potentially effective therapeutic agent for hepatocellular carcinoma patients with tumors expressing fibroblast growth factor 19.Mol Cancer Ther; 16(1); 68-75.©2016 AACR.
|
27837028 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that ASP5878 is a potentially effective therapeutic agent for hepatocellular carcinoma patients with tumors expressing fibroblast growth factor 19.
|
27837028 |
2017 |